Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

After Death Of Cipla Former Joint Managing Director Amar Lulla, Will Vision Of Veteran Continue?

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - After jointly serving at the helm of Cipla for more than three decades, Joint Managing Director Amar Lulla died April 22 after a prolonged and debilitating battle with cancer. To the world, Cipla Chairman Yusuf Hamied was the face of the company - fighting global pharmaceutical companies to bring down prices of anti-HIV and anti-cancer medications - but to those within the organization, Lulla remained the single driving force, handling the complexities of the generic drugs market in India and working steadily to keep Cipla competitive
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

SC077732

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel